id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-1972-0003,FDA,FDA-2019-E-1972,Letter from FDA to U.S. Patent and Trademark Office,Other,Letter(s),2019-06-21T04:00:00Z,2019,6,2019-06-21T04:00:00Z,,2019-06-21T14:49:41Z,,0,0,0900006483d31171
FDA-2019-E-1972-0001,FDA,FDA-2019-E-1972,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2019-04-24T04:00:00Z,2019,4,2019-04-24T04:00:00Z,,2019-04-24T14:52:03Z,,0,0,0900006483beaef2
FDA-2019-E-1972-0002,FDA,FDA-2019-E-1972,Patent Extension Application from Eli Lilly & Company (on behalf of Incyte Corporation),Other,Application,2019-04-24T04:00:00Z,2019,4,2019-04-24T04:00:00Z,,2019-04-24T14:55:58Z,,0,0,0900006483beaef4